raloxifene hydrochloride has been researched along with ly2066948 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bryant, HU; Cohen, IR; Dally, RD; Dodge, JA; Fong, KC; Frank, SA; Geiser, AG; Hinklin, R; Hummel, CW; Jones, SA; Lewis, G; McCann, DJ; Rudmann, DG; Shepherd, TA; Tian, H; Wallace, OB; Wang, M; Wang, Y | 1 |
| Azam, F; Chennathukuzhi, VM; Harris, HA; Huselton, C; Jelinsky, SA; Mekonnen, B; Negahban, A; Patel, VS; Schelling, SH; Winneker, RC; Zhang, X | 1 |
2 other study(ies) available for raloxifene hydrochloride and ly2066948
| Article | Year |
|---|---|
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
Topics: Animals; Binding Sites; Biological Availability; Cell Line; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Leiomyoma; Mammary Glands, Animal; Models, Molecular; Naphthalenes; Organ Size; Ovary; Piperidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Uterine Neoplasms; Uterus | 2005 |
Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats.
Topics: Animals; Biomarkers; Brain; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Female; Naphthalenes; Ovarian Cysts; Ovary; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Steroid 17-alpha-Hydroxylase; Up-Regulation | 2008 |